An observational study in COVID-19, sponsored by Huashan Hospital. Recruiting at 1 site in China. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2022-05-24.
Sponsored by Huashan Hospital · Observational
The study was designed to analyze the efficacy and safety of Paxlovid for the treatment of COVID-19.
The study is a real-world study and the case records of patients with COVID-19 who visit Huashan Hospital affiliated to Fudan University from 2022 to 2027 and receive Paxlovid therapy will be collected in this study. The medical data including patient demographic, clinical characteristics, laboratory examination, history of treatments, adverse reactions and treatment outcome will be extracted to analyze the effectivity and safety of paxlovid and explore the prognosis-relevant factors of COVID-19.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's planned enrollment of 2,000 is above the median of 261 across 3,136 observational studies indexed under COVID-19.
Browse COVID-19 studies →Huashan Hospital is the lead sponsor of 239 studies on the registry; 102 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with COVID-19 who were admitted to Huashan Hospital, Fudan University from 2022 to 2027
Exclusion Criteria:
Patients with COVID-19 who visit Huashan Hospital,Fudan University from 2022 to 2027 and receive Paxlovid therapy
Drug: Paxlovid
Patients with COVID-19 who visit Huashan Hospital,Fudan University from 2022 to 2027 and receive routine therapy without paxlovid
The study is a real-world study. According to the actual medical history of patients, the usage of paxlovid will be collected.
Viral shedding time
time from the first positive testing to the first day of nucleic acid Ct value\> 35 for both ORF1ab and N gene (in two consecutive).
Time frame: up to 28 days
Percentage of the participants who have progression of COVID-19
Percentage of participants who experience these events by Day 28 Progress to severe and/or critical COVID-19; Death from any cause
Time frame: up to 28 days
AEs and SAEs through Day 28
Adverse events and Serious adverse events through Day 28
Time frame: up to 28 days
Percentage of participants who turned negative for SARS-CoV-2
Percentage of participants who turned negative for SARS-COV-2 at Day 3, 5, 7, 10, 14
Time frame: up to 28 days
Time to sustained clinical recovery
Time to sustained clinical recovery
Time frame: up to 28 days
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Huashan Hospital